vs

Side-by-side financial comparison of Steris (STE) and Trade Desk (The) (TTD). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $846.8M, roughly 1.8× Trade Desk (The)). Trade Desk (The) runs the higher net margin — 22.1% vs 12.9%, a 9.2% gap on every dollar of revenue. On growth, Trade Desk (The) posted the faster year-over-year revenue change (14.3% vs 9.2%). Trade Desk (The) produced more free cash flow last quarter ($285.3M vs $199.5M). Over the past eight quarters, Trade Desk (The)'s revenue compounded faster (31.3% CAGR vs 15.8%).

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

The Trade Desk, Inc. is an American multinational technology company that specializes in real-time programmatic marketing automation technologies, products, and services, designed to personalize digital content delivery to users.

STE vs TTD — Head-to-Head

Bigger by revenue
STE
STE
1.8× larger
STE
$1.5B
$846.8M
TTD
Growing faster (revenue YoY)
TTD
TTD
+5.1% gap
TTD
14.3%
9.2%
STE
Higher net margin
TTD
TTD
9.2% more per $
TTD
22.1%
12.9%
STE
More free cash flow
TTD
TTD
$85.8M more FCF
TTD
$285.3M
$199.5M
STE
Faster 2-yr revenue CAGR
TTD
TTD
Annualised
TTD
31.3%
15.8%
STE

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
STE
STE
TTD
TTD
Revenue
$1.5B
$846.8M
Net Profit
$192.9M
$186.9M
Gross Margin
43.8%
80.7%
Operating Margin
18.3%
30.3%
Net Margin
12.9%
22.1%
Revenue YoY
9.2%
14.3%
Net Profit YoY
11.2%
2.6%
EPS (diluted)
$1.96
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
STE
STE
TTD
TTD
Q4 25
$1.5B
$846.8M
Q3 25
$1.5B
$739.4M
Q2 25
$1.4B
$694.0M
Q1 25
$1.5B
$616.0M
Q4 24
$1.4B
$741.0M
Q3 24
$1.3B
$628.0M
Q2 24
$1.3B
$584.5M
Q1 24
$1.1B
$491.3M
Net Profit
STE
STE
TTD
TTD
Q4 25
$192.9M
$186.9M
Q3 25
$191.9M
$115.5M
Q2 25
$177.4M
$90.1M
Q1 25
$145.7M
$50.7M
Q4 24
$173.5M
$182.2M
Q3 24
$150.0M
$94.2M
Q2 24
$145.4M
$85.0M
Q1 24
$-1.4M
$31.7M
Gross Margin
STE
STE
TTD
TTD
Q4 25
43.8%
80.7%
Q3 25
44.2%
78.1%
Q2 25
45.1%
78.2%
Q1 25
43.3%
76.8%
Q4 24
44.5%
81.7%
Q3 24
43.6%
80.5%
Q2 24
44.7%
81.1%
Q1 24
40.2%
78.9%
Operating Margin
STE
STE
TTD
TTD
Q4 25
18.3%
30.3%
Q3 25
18.2%
21.8%
Q2 25
17.7%
16.8%
Q1 25
14.6%
8.8%
Q4 24
17.9%
26.4%
Q3 24
16.5%
17.3%
Q2 24
14.5%
16.2%
Q1 24
22.0%
5.8%
Net Margin
STE
STE
TTD
TTD
Q4 25
12.9%
22.1%
Q3 25
13.1%
15.6%
Q2 25
12.8%
13.0%
Q1 25
9.8%
8.2%
Q4 24
12.7%
24.6%
Q3 24
11.3%
15.0%
Q2 24
11.4%
14.5%
Q1 24
-0.1%
6.4%
EPS (diluted)
STE
STE
TTD
TTD
Q4 25
$1.96
$0.39
Q3 25
$1.94
$0.23
Q2 25
$1.79
$0.18
Q1 25
$1.48
$0.10
Q4 24
$1.75
$0.36
Q3 24
$1.51
$0.19
Q2 24
$1.46
$0.17
Q1 24
$-0.02
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
STE
STE
TTD
TTD
Cash + ST InvestmentsLiquidity on hand
$423.7M
$1.3B
Total DebtLower is stronger
$1.9B
Stockholders' EquityBook value
$7.2B
$2.5B
Total Assets
$10.6B
$6.2B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
STE
STE
TTD
TTD
Q4 25
$423.7M
$1.3B
Q3 25
$319.2M
$1.4B
Q2 25
$279.7M
$1.7B
Q1 25
$171.7M
$1.7B
Q4 24
$155.2M
$1.9B
Q3 24
$172.2M
$1.7B
Q2 24
$198.3M
$1.5B
Q1 24
$207.0M
$1.4B
Total Debt
STE
STE
TTD
TTD
Q4 25
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
STE
STE
TTD
TTD
Q4 25
$7.2B
$2.5B
Q3 25
$7.0B
$2.6B
Q2 25
$7.0B
$2.7B
Q1 25
$6.6B
$2.7B
Q4 24
$6.4B
$2.9B
Q3 24
$6.6B
$2.6B
Q2 24
$6.4B
$2.4B
Q1 24
$6.3B
$2.2B
Total Assets
STE
STE
TTD
TTD
Q4 25
$10.6B
$6.2B
Q3 25
$10.4B
$5.9B
Q2 25
$10.4B
$6.0B
Q1 25
$10.1B
$5.7B
Q4 24
$10.0B
$6.1B
Q3 24
$10.2B
$5.5B
Q2 24
$10.1B
$5.2B
Q1 24
$11.1B
$4.7B
Debt / Equity
STE
STE
TTD
TTD
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
STE
STE
TTD
TTD
Operating Cash FlowLast quarter
$298.2M
$311.6M
Free Cash FlowOCF − Capex
$199.5M
$285.3M
FCF MarginFCF / Revenue
13.3%
33.7%
Capex IntensityCapex / Revenue
6.6%
3.1%
Cash ConversionOCF / Net Profit
1.55×
1.67×
TTM Free Cash FlowTrailing 4 quarters
$917.1M
$795.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
STE
STE
TTD
TTD
Q4 25
$298.2M
$311.6M
Q3 25
$287.8M
$224.7M
Q2 25
$420.0M
$165.0M
Q1 25
$260.8M
$291.4M
Q4 24
$332.8M
$199.4M
Q3 24
$250.7M
$273.3M
Q2 24
$303.7M
$81.3M
Q1 24
$254.8M
$185.5M
Free Cash Flow
STE
STE
TTD
TTD
Q4 25
$199.5M
$285.3M
Q3 25
$201.3M
$158.3M
Q2 25
$326.4M
$119.8M
Q1 25
$189.9M
$232.3M
Q4 24
$243.6M
$179.2M
Q3 24
$148.8M
$224.6M
Q2 24
$195.7M
$59.1M
Q1 24
$163.3M
$178.2M
FCF Margin
STE
STE
TTD
TTD
Q4 25
13.3%
33.7%
Q3 25
13.8%
21.4%
Q2 25
23.5%
17.3%
Q1 25
12.8%
37.7%
Q4 24
17.8%
24.2%
Q3 24
11.2%
35.8%
Q2 24
15.3%
10.1%
Q1 24
14.6%
36.3%
Capex Intensity
STE
STE
TTD
TTD
Q4 25
6.6%
3.1%
Q3 25
5.9%
9.0%
Q2 25
6.7%
6.5%
Q1 25
4.8%
9.6%
Q4 24
6.5%
2.7%
Q3 24
7.7%
7.8%
Q2 24
8.4%
3.8%
Q1 24
8.2%
1.5%
Cash Conversion
STE
STE
TTD
TTD
Q4 25
1.55×
1.67×
Q3 25
1.50×
1.94×
Q2 25
2.37×
1.83×
Q1 25
1.79×
5.75×
Q4 24
1.92×
1.09×
Q3 24
1.67×
2.90×
Q2 24
2.09×
0.96×
Q1 24
5.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

TTD
TTD

Other$427.2M50%
Non Us$419.6M50%

Related Comparisons